Toll-Like Receptors New Therapeutic Targets for the Treatment of Atherosclerosis, Acute Coronary Syndromes, and Myocardial Failure
被引:40
作者:
Erickson, Benjamin
论文数: 0引用数: 0
h-index: 0
机构:
Oregon Hlth & Sci Univ, Dept Internal Med, Portland, OR 97201 USANew York Med Coll, Dept Med, Westchester Med Ctr, Valhalla, NY 10595 USA
Erickson, Benjamin
[3
]
Sperber, Kirk
论文数: 0引用数: 0
h-index: 0
机构:
New York Med Coll, Div Rheumatol Allergy & Immunol, Westchester Med Ctr, Valhalla, NY 10595 USANew York Med Coll, Dept Med, Westchester Med Ctr, Valhalla, NY 10595 USA
Sperber, Kirk
[2
]
Frishman, William H.
论文数: 0引用数: 0
h-index: 0
机构:
New York Med Coll, Dept Med, Westchester Med Ctr, Valhalla, NY 10595 USANew York Med Coll, Dept Med, Westchester Med Ctr, Valhalla, NY 10595 USA
Frishman, William H.
[1
]
机构:
[1] New York Med Coll, Dept Med, Westchester Med Ctr, Valhalla, NY 10595 USA
[2] New York Med Coll, Div Rheumatol Allergy & Immunol, Westchester Med Ctr, Valhalla, NY 10595 USA
[3] Oregon Hlth & Sci Univ, Dept Internal Med, Portland, OR 97201 USA
The toll-like receptors (TLRs) are a class of transmembrane molecules that have important functions in both innate and acquired immunity. As part of the body's normal immune defense against microbial pathogens, stimulation of these receptors will trigger the inflammatory response cascade and the release of cytokines. Activation of these receptors also plays a role in a variety of systemic inflammatory diseases such as asthma, sepsis, atherosclerosis, acute corollary artery disease, and left ventricular remodeling. Pharmacologic approaches to modify the actions of TLRs are now under consideration as potential treatments for inflammatory systemic diseases that include atherosclerosis. At the same time, it is essential to characterize the benefits and risks of modifying such all important part of the body's innate immune system.